A minority of chronic myeloid leukemia patients (CML) express a variety of atypical <i>BCR-ABL1</i> fusion variants and, of these, the e6a2 <i>BCR-ABL1</i> fusion is generally associated with an aggressive disease course. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.